Followers | 399 |
Posts | 18568 |
Boards Moderated | 0 |
Alias Born | 04/28/2009 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, November 22, 2016 9:07:27 PM
Revenues and Cost of Sales
The Company had revenues of $83,500 and $209,573 for the three and nine months ended September 30,2016, respectively, compared to revenues of $1,755 and $20,212 for the three and nine months ended September 30,
2015, respectively. The Company generated revenues primarily from sales of its TetraStem antibiotic which presently is sold primarily through local physicians and the license fee. Cost of sales was ($5,984) and ($8,298) for the three and nine months ended September 30, 2016, respectively, compared to cost of sales of ($7,661) and ($9,886) for the three and nine months ended September 30, 2015, respectively. We expect sales to grow during the latter part of 2016 as we build awareness for our products and attempt to sell to larger pharmaceutical product retailers. We also
expect margins to improve if we are successful in selling larger volumes of our products.
EVERYTHING I WRITE IS ONLY MY OPINION!! SO DON'T BUY OR SELL!
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM